EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Metabolomics and Precision Medicine in Resistant Hypertension: Pathophysiological Insights, Biomarker Discovery, and Translational Strategies

Yu Ra Lee iD, Miri Park, Yoon Shin Cho iD, Ho-Young Park iD

International Journal of Hypertension · 2026-01 · 2026 (1)

DOI: 10.1155/ijhy/9656975 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Hypertension, online erschienen am 14.07.2026. Verfasst von Yu Ra Lee und 3 weiteren Autor:innen. Beteiligte Einrichtung: Food Functionality Research Division, Korea Food Research Institute, Wanju-gun, Jeollabuk-do, 55365, South Korea, kfri.re.kr. Die Arbeit nennt 124 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Korea National Institute of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Resistant hypertension (RH), defined as uncontrolled blood pressure despite the use of at least three optimally dosed antihypertensive agents, including a diuretic, remains a major clinical challenge associated with elevated cardiovascular risk. Metabolomics offers a dynamic approach to characterize biochemical perturbations related to amino acid metabolism, lipid remodeling, mitochondrial dysfunction, oxidative stress, renal impairment, and gut microbiota–derived metabolites. However, current evidence remains limited by small sample sizes, cross‐sectional designs, heterogeneous definitions of RH, inadequate exclusion of pseudoresistance, medication confounding, and limited external validation. This structured narrative review synthesizes RH‐specific metabolomic evidence and distinguishes it from findings extrapolated from broader hypertension populations. We further discuss methodological challenges, replication gaps, pharmacometabolomic confounding, and validation standards required for clinical implementation. Integrating metabolomics with clinical phenotyping, genomics, proteomics, and microbiome profiling may eventually support RH phenotyping, treatment–response prediction, and biomarker‐guided precision medicine, but large longitudinal cohorts with confirmed true RH are needed before clinical translation.

Schlagwörter

Stichwörter der Autor:innen

biomarker discoverymetabolomicsmultiomicsprecision medicineresistant hypertension

Autor:innen und Institutionen

  • Food Functionality Research Division, Korea Food Research Institute, Wanju-gun, Jeollabuk-do, 55365, South Korea, kfri.re.kr.
  • Department of Biomedical Science, Hallym University, Chuncheon-si, Gangwon-do, 24252, South Korea, hallym.ac.kr.
  • Department of Food Biotechnology, Korea National University of Science and Technology, Daejeon, 34113, South Korea.

ORCID-Profile: Yu Ra Lee, Yoon Shin Cho, Ho-Young Park

Förderung

  • Korea National Institute of Health

Zitieren

APA

Lee, Y. R., Park, M., Cho, Y. S., & Park, H. Y. (2026). Metabolomics and Precision Medicine in Resistant Hypertension: Pathophysiological Insights, Biomarker Discovery, and Translational Strategies. International Journal of Hypertension, 2026(1). https://doi.org/10.1155/ijhy/9656975

Vancouver

Lee YR, Park M, Cho YS, Park HY. Metabolomics and Precision Medicine in Resistant Hypertension: Pathophysiological Insights, Biomarker Discovery, and Translational Strategies. International Journal of Hypertension. 2026;2026(1). doi:10.1155/ijhy/9656975

BibTeX
@article{Lee2026,
  author = {Lee, Yu Ra and Park, Miri and Cho, Yoon Shin and Park, Ho-Young},
  title = {Metabolomics and Precision Medicine in Resistant Hypertension: Pathophysiological Insights, Biomarker Discovery, and Translational Strategies},
  journal = {International Journal of Hypertension},
  year = {2026},
  volume = {2026},
  number = {1},
  doi = {10.1155/ijhy/9656975}
}
Kostenlos starten →